Literature DB >> 19239227

C-myc amplification altered the gene expression of ABC- and SLC-transporters in human breast epithelial cells.

Keon Wook Kang1, Young Bin Im, Woon-Jung Go, Hyo-Kyung Han.   

Abstract

The present study aimed to investigate the effect of c-Myc overexpression on the gene expression and functional activity of major drug transporters in breast epithelial cells. In order to reflect c-Myc overexpressed epithelial cells, MCF10A cells (human mammary epithelial cells) stably expressing c-Myc (c-Myc-MCF10A cells) have been established by retroviral infection and then the effect of c-Myc activation on the gene expression and functional activity of 16 influx and efflux transporters was examined in c-Myc-MCF10A cells. In RT-PCR analysis, the quantitative difference in transporters' gene expression profiles was observed after c-Myc activation. Western blot analysis also indicated that the protein expression of some transporters (MCT1, OCT1, MRP1, MRP2 and BCRP) increased by c-Myc overexpression. In parallel to the alteration in gene expression, functional activity studies indicated that the cellular uptake of benzoic acid, MPP+, calcein-AM, H33342, representative substrates of MCT1, OCT1, MRPs and BCRP, respectively, was significantly (p < 0.05) altered by c-Myc overexpression. In conclusion, c-Myc amplification appeared to be coupled with the modulation of gene expression of certain drug transporters in human breast epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19239227     DOI: 10.1021/mp800116f

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  15 in total

Review 1.  Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

Authors:  Karthika Natarajan; Yi Xie; Maria R Baer; Douglas D Ross
Journal:  Biochem Pharmacol       Date:  2012-01-11       Impact factor: 5.858

2.  Rare Variants in the ABCG2 Promoter Modulate In Vivo Activity.

Authors:  Rachel J Eclov; Mee J Kim; Robin Smith; Nadav Ahituv; Deanna L Kroetz
Journal:  Drug Metab Dispos       Date:  2018-02-21       Impact factor: 3.922

3.  Selective GPR55 antagonism reduces chemoresistance in cancer cells.

Authors:  Nagendra S Singh; Michel Bernier; Irving W Wainer
Journal:  Pharmacol Res       Date:  2016-07-14       Impact factor: 7.658

Review 4.  Regulation of colonic epithelial butyrate transport: Focus on colorectal cancer.

Authors:  Pedro Gonçalves; Fátima Martel
Journal:  Porto Biomed J       Date:  2016-07-01

5.  Novel roles of peroxiredoxins in inflammation, cancer and innate immunity.

Authors:  Tetsuro Ishii; Eiji Warabi; Toru Yanagawa
Journal:  J Clin Biochem Nutr       Date:  2012-02-18       Impact factor: 3.114

6.  Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.

Authors:  Ryan J O Dowling; Saroj Niraula; Martin C Chang; Susan J Done; Marguerite Ennis; David R McCready; Wey L Leong; Jaime M Escallon; Michael Reedijk; Pamela J Goodwin; Vuk Stambolic
Journal:  Breast Cancer Res       Date:  2015-03-03       Impact factor: 6.466

7.  Lactate, a putative survival factor for myeloma cells, is incorporated by myeloma cells through monocarboxylate transporters 1.

Authors:  Shiho Fujiwara; Naoko Wada; Yawara Kawano; Yutaka Okuno; Yoshitaka Kikukawa; Shinya Endo; Nao Nishimura; Nina Ueno; Hiroaki Mitsuya; Hiroyuki Hata
Journal:  Exp Hematol Oncol       Date:  2015-04-21

8.  Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer.

Authors:  Ho Kyung Seo; Kyung-Ohk Ahn; Nae-Rae Jung; Ji-Sun Shin; Weon Seo Park; Kang Hyun Lee; Sang-Jin Lee; Kyung-Chae Jeong
Journal:  Oncotarget       Date:  2014-01-30

9.  DiME: a scalable disease module identification algorithm with application to glioma progression.

Authors:  Yunpeng Liu; Daniel A Tennant; Zexuan Zhu; John K Heath; Xin Yao; Shan He
Journal:  PLoS One       Date:  2014-02-11       Impact factor: 3.240

10.  Knockdown of SALL4 inhibits the proliferation and reverses the resistance of MCF-7/ADR cells to doxorubicin hydrochloride.

Authors:  Yuan-Yuan Chen; Zhi-Zhen Li; Yuan-Yuan Ye; Feng Xu; Rui-Jie Niu; Hong-Chen Zhang; Yi-Jian Zhang; Ying-Bin Liu; Bao-San Han
Journal:  BMC Mol Biol       Date:  2016-03-02       Impact factor: 2.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.